CSL Ltd (CSL.AX)
6 Dec 2013
|Market Cap (Mil.):||$32,765.72|
|Shares Outstanding (Mil.):||486.86|
SYDNEY, Oct 16 - Australian blood products maker CSL Ltd said it expected slightly lower profit growth in the current business year as litigation costs weigh but added that it planned to buy back shares of up to A$950 million ($905 million).
SYDNEY, Oct 8 - Australian shares slipped 0.2 percent to one-month lows on Tuesday morning as a lack of progress in resolving the U.S. budget standoff kept buyers at bay, while a rebound in CSL shares limited the broad market losses.
SYDNEY, Aug 14 - Australia's CSL Ltd, the world's No.2 blood products maker, reported a 19 percent rise in full-year net profit to $1.22 billion on Wednesday, after strong sales of its core products offset a strong Australian dollar.
SYDNEY, Aug 13 - Australian shares rose 0.1 percent on Tuesday, buoyed by a better-than-expected earnings season so far, with CSL shares underpinning the market with banks and miners lending some support.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
CSL Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.